Huntington's disease (HD) is a neurodegenerative disorder caused by expansion of a CAG repeat in the gene encoding for Huntingtin (Htt), which results in progressive degeneration of the striatal GABAergic/enkephalin neurons. These neurons express both the A 2A and D 2 receptors, which stimulate and inhibit adenylyl cyclase, respectively. In this study we analyzed the possibility of an involvement of the A 2A receptor and its signaling components in the pathogenesis of HD. We report here that striatal cells expressing mutant Htt exhibit increased binding affinities for the selective A 2A receptor ligand 3 H-SCH-58261. Furthermore, despite identical basal adenylyl cyclase activity in all cells, forskolin, a direct activator of this enzyme, significantly overstimulated cAMP production in mutant Htt cells with respect to parental or wild-type Htt-expressing cells. MichaelisMenten analysis of forskolin-stimulated enzyme activity revealed a specific decrease of Km value in mutant Htt cells, indicating increased sensitivity for the substrate. Remarkably, coupling of the A 2A receptor to adenylyl cyclase was also aberrantly increased. Nevertheless, in all clones, stimulation of cAMP production by 10 -7 M NECA was fully counteracted by selective A 2A receptor antagonists. Altogether, these data suggest that expression of mutant Htt induces an amplification of adenylyl cyclase-transduced signals and an aberrant coupling of the A 2A receptor to this transduction system. Given the involvement of adenylyl cyclase in key physiological functions, including cell growth and cell survival, we speculate that these changes may alter the susceptibility of striatal neurons to cell death and may contribute to the development of HD.
responsible for mutant Htt pathogenicity are still largely unknown, but may involve a proteolytic cleavage of the protein to generate fragments that aggregate into the nucleus and cytoplasm (8, 9) . Much less clear is the mechanism by which, despite ubiquitous expression of mutant (and normal) Htt in HD patients, selective degeneration of striatal medium spiny neurons occurs in the disease.
Adenosine is a neurotransmitter whose actions are mediated by four G-protein-coupled receptors (the A 1 , A 2A , A 2B , and A 3 receptors, 10). Adenosine agonists induce potent psychomotor depression and inhibit the locomotor activity induced by dopamine agonists (11) . This adenosine-dopamine interaction mainly depends on a postsynaptic A 2A receptor-D 2 receptor interaction in striatum (11) . In this brain area, A 2A receptors are coexpressed with D 2 receptors on GABAergic enkephalin neurons, which are key components of the "indirect" striatal efferent pathway involved in regulation of motor activity, and are highly affected in HD (12) . By activating A 2A receptors on these neurons, adenosine acts as a dopamine functional antagonist. It is interesting that A 2A receptors stimulate and D 2 receptor inhibit adenylyl cyclase, which represents a key target in mediating the opposite effects of these two transmitters (11) .
A marked decrease of A 2A receptors in postmortem basal ganglia of four patients with Huntington's chorea has been reported (13) . This report has been partially supported by studies performed in transgenic mice expressing mutant Htt's amino terminus; that is, exon1 (14) . However, these changes may still be subsequent to or independent of earlier aberrant receptor(s) function.
Therefore, the possibility remains strong that changes in the adenosine-dopamine system in striatum play a role in the motor dysfunction typical of HD. It has been suggested that adenosine triggers development-associated apoptosis (for review, see ref 15) ; under specific conditions, activation of the A 2A adenosine receptor may result in cell death (15, 16) . It may hence be hypothesized that a dysregulation of adenosine-mediated cell death, likely due to an alteration of A 2A receptor expression or function, may contribute to neurodegeneration in HD.
Here we tested the possibility that mutant Htt may alter A 2A receptor signaling. In particular, we found that striatal cells expressing mutant Htt (3) show an aberrant amplification of cAMP formation upon exposure to either forskolin or, more remarkably, adenosine receptor agonists, which suggests a specific interaction of mutant Htt with this transduction system. We speculate that such changes may contribute to the development of HD. It is interesting that selective A 2A receptor antagonists retained their ability to fully counteract A 2A receptor-mediated cyclase stimulation also in mutant Htt-expressing cells, hence highlighting for the first time a potential use of these compounds in the pharmacological treatment of HD. 
MATERIALS AND METHODS

Materials
Cell Culture
Parental ST14A cells and stable subclones expressing either 548 aminoacids N terminal to the protein in the wild-type (N548wt) or mutant (N548mu) versions, or the full-length wild-type (FLwt) and full-length mutant (FLmu) proteins (3) were grown at 33°C in the presence of Dulbecco's modified Eagle medium supplemented with 10% fetal bovine serum as previously described (17) . All transfected subclones have been previously demonstrated to express the exogenous proteins at comparable levels at least up to 25 passages in culture (3). Expression levels are routinely checked by Western blot in early passaged cells. Cells were used when 80% confluent.
Reverse transcriptase-polymerase chain reaction (RT-PCR)
Total RNA was prepared from cells and tissue using Triazol Reagent (Gibco, BRL, Rockville, Md. 
Receptor binding studies
Cells were washed with phosphate buffered saline and scraped off T75 flasks in ice-cold hypotonic buffer (5 mM Tris HCl, 2 mM EDTA, pH 7.4). The cell suspension was homogenized with Polytron, and the homogenate was spun for 10 min at 1,000 g. The supernatant, collected in pools from 6 to 8 culture dishes, was then centrifuged for 30 min at 48,000 g, and each pool was used to perform a single saturation experiment. (20) . The protein concentration was determined according to a Bio Rad method (21) with bovine serum albumin as a standard reference. Binding assays were carried out as previously described (22) . In saturation studies, cell membranes were incubated for 60 min at 4°C with 8-10 different concentrations of either 3 H-SCH 58261 or 3 H-ZM 241385 (0.05-10 nM) in a total volume of 250 µl containing 50 mM Tris HCl, 120 mM NaCl, 5 mM KCl, 10 mM MgCl 2 , and 2 mM CaCl 2 , pH 7.4. Nonspecific binding was defined as binding in the presence of 10 µM NECA and was about 40% of total binding. Bound and free radioactivity were separated by filtering the assay mixture through Whatman GF/B glass-fiber filters by using a Micro-Mate 196 cell harvester (Packard). The filterbound radioactivity was counted by using a microplate scintillation counter (Top Count) at an efficiency of 57% with Micro Scint 20. A weighted nonlinear least-squares curve-fitting program LIGAND (23), was used for computer analysis of saturation experiments.
Measurement of cAMP levels
Cells were washed in phosphate buffered saline and centrifuged for 10 min at 200 g. The supernatant was discarded, the pellet was resuspended in a buffer containing 120 mM NaCl, 5 mM KCl, 0.37 mM NaH 2 PO 4 , 10 mM MgCl 2 , 2 mM CaCl 2 , 5 g/L D-glucose, 10 mM HepesNaOH, pH 7.4, and centrifuged again for 10 min at 200 g. Cells (4 × 10 5 cells/tube) were then suspended in 0.5 ml incubation mixture (120 mM NaCl, 5 mM KCl, 0.37 mM NaH 2 PO 4 , 10 mM MgCl 2 , 2 mM CaCl 2 , 5 g/L D-glucose, 10 mM Hepes-NaOH, pH 7.4) containing 1.0 I.U. of adenosine deaminase/ml and 0.5 mM 4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone, RO 201724, as phosphodiesterase inhibitor) and preincubated for 10 min in a shaking bath at 37°C. Then forskolin (1 µM) or NECA (1 nM-10 µM) was added to the mixture, and the incubation continued for a further 5 min. The effect of several A 2A receptor antagonists such as CGS 15943 (1 µM), ZM 241385 (1 µM), and SCH 58261 (1 µM) was determined by antagonism of NECA (100 nM)-induced stimulation of cyclic AMP levels. The reaction was terminated by the addition of cold 6% trichloroacetic acid (TCA). The TCA suspension was centrifuged at 2,000 g for 10 min at 4°C, and the supernatant was extracted four times with water-saturated diethyl ether. The final aqueous solution was tested for cyclic AMP levels by a competition protein-binding assay carried out as previously described (24) . Samples of cyclic AMP standards (0-10 pmol) were added to each test tube containing trizma base 0.1 M, aminophylline 8.0 mM, 2 mercaptoethanol 6.0 mM, pH 7.4, and 3 H-cAMP in a total volume of 0.5 ml. The binding protein, previously prepared from beef adrenals, was added to the samples previously incubated at 4° C for 150 min. The samples, after the addition of charcoal, were centrifuged at 2,000 g for 10 min. The clear supernatant (0.2 ml) was mixed with 4 ml of Ultimagold XR (Hewlett-Packard) and counted in a LS-1800 Beckman scintillation counter.
RESULTS
Presence of the A 2A adenosine receptor in ST14A cells and in Htt expressing subclones. Striatal ST14A cells have been previously stably transfected with either normal or mutant full-length and truncated Htt constructs to generate a large number of stable subclones (3). The rationale for extending the analysis to the phenotype of cells expressing truncated Htts derives from wellestablished data demonstrating that N-terminal fragments resulting from proteolytic cleavage of full-length mutant Htt are more toxic than the full-length protein itself (9) . Figure 1 shows A 2A receptor mRNA levels in parental ST14A cells and in the various stable subclones expressing N548wt, N548mu, FLwt, and FLmu cDNAs. As a positive control, mRNAs from adult rat striatum, cortex, and A 2A receptor stably transfected CHO cells were loaded. As expected, RT-PCR revealed an enrichment of the A 2A receptor in striatum and in transfected CHO cells, with lower levels in rat cortex, in agreement with previous reports on the brain distribution of this receptor subtype (25) . Both parental ST14A cells, which are striatum-derived, and all stable subclones express the 630 bps band corresponding to the A 2A receptor mRNA, although to a different extent (see also below).
Despite differences in mRNA levels, comparable A 2A receptor protein densities are found in all clones, as shown by radio-ligand binding studies performed with the highly selective A 2A receptor antagonist 3 H-SCH 58261 (Table 1) . Scatchard-plot analysis revealed the presence of a single class of specific, high-affinity, and saturable binding sites in both ST14A and in Httexpressing cells, with comparable Bmax values, independently of the presence of normal or mutant Htt (Table 1) . Kd values were instead significantly reduced in FLmu cells with respect to parental ST14A cells, a change that was even more significant in N548mu cells (Table 1 corresponding Bmax values were 92 ± 6; 90 ± 8; 90 ± 6; 93 ± 5; 90 ± 3 fmol/mg protein.
No changes of Kd values were detected in clones expressing either FLwt or N548wt (Table 1) . These data suggest a selective increase of binding affinity in the presence of mutant Htt.
In Figure 2 we report an example of saturation analysis performed with 3 H-SCH 58261 (0.5-10 nM) in parental ST14A cells and in N548mu (A) or FLmu (B) cells. Consistent with the Kd values reported in Table 1 , at low radioligand concentrations (0.5-4.5 nM), an increase of binding values was detected in both N548mu and FLmu cells, as demonstrated by the shift to the left of 3 H-SCH 58261 saturation curves ( Fig. 2A, B) .
Selective alteration of forskolin-stimulated adenylyl cyclase response in cells expressing mutant Htt
The A 2A adenosine receptor is coupled to stimulation of adenylyl cyclase via Gs stimulatory proteins, which leads to increases of cAMP formation (10) . We therefore analyzed the sensitivity of adenylyl cyclase to pharmacological agents that are known to specifically activate this effector system. Despite no changes of basal enzyme activity (Table 2) , response of adenylyl cyclase to the direct activator forskolin (used in the presence of the cAMP-dependent phosphodiesterase inhibitor RO 201724) was notably increased in N548mu (and Flmu) cells with respect to parental or wild-type Htt cells. As shown in Table 2 , an amplification of cAMP formation was already demonstrable with forskolin alone in N548mu cells.
To shed light on the cyclase alteration observed in cells expressing mutant Htt, we performed a Michaelis-Menten analysis of adenylyl cyclase activity in ST14A and N548mu cells. We therefore incubated cell homogenates in the presence of a fixed forskolin concentration and in the presence of graded concentrations of substrate (0.001-1000 µM ATP, see x-axis of Fig. 3A) . Analysis of the data reported in Figure 3A , according to Lineweaver-Burk (Fig. 3B) 
Aberrant amplification of A 2A receptor-dependent adenylyl cyclase in cells expressing mutant Htt
When the adenosine analog NECA was applied to the cells, an aberrant amplification of adenylyl cyclase response was detected selectively in cells expressing mutant Htt. In all clones, NECA (0.1 nM-10 µM) significantly increased cAMP production in a concentration-dependent manner. However, as shown in Figure 4 , which reports the log dose-response curve for NECA in cells expressing either N548wt These results suggest a selective increase of responsiveness of the adenosine A 2A receptor/adenylyl cyclase system in the presence of mutant Htt. This change is unrelated to modifications of endogenously produced adenosine because adenosine deaminase was present during the adenylyl cyclase assay.
Selective A 2A receptor antagonists revert A 2A -stimulated cAMP formation in both parental and Htt-expressing cells
To further confirm that the effect induced by NECA on cAMP formation is due to stimulation of the A 2A receptor subtype, we performed experiments in the presence of adenosine receptor antagonists characterized by various degree of selectivity towards the A 2A adenosine receptor subtype (for review, see 26). As shown in Table 3 , in ST14A cells, both the relatively selective antagonists CGS15943 and ZM 241385 and the highly selective antagonist SCH 58261, completely prevented the increases of cAMP induced by NECA at an agonist concentration (100 nM), which selectively stimulates adenylyl cyclase via the A 2A receptor. Remarkably, all the tested antagonists retained the ability to counteract NECA-induced cAMP formation also in cells expressing mutant Htt, where adenylyl cyclase activity is aberrantly increased with respect to ST14A and to wild-type Htt cells.
DISCUSSION
The A 2A adenosine receptor plays an important role in striatal function (11) . By activating this receptor subtype in striatal medium spiny neurons, adenosine acts as a dopamine functional antagonist and inhibits the indirect efferent striatal pathway involved in regulation of motor activity. Hence, an intact A 2A receptor function is needed to preserve an integrated regulation of motor behavior. Besides the involvement of this receptor subtype in motor function, recent data have highlighted its possible role in cell survival, which suggests that its activation under specific pathological conditions may contribute to neurodegeneration in ischemic-like diseases (for review, see 27). (14, 30) . On the contrary, binding autoradiography for glutamate NMDA receptors showed no difference with respect to age-matched control animals, which supports the concept that specific receptor systems may be selectively affected in HD. Moreover, receptor down-regulation seems to appear before the onset of observable symptoms (30, 31) . Yet, such changes may still be subsequent to or independent from earlier aberrant receptor(s) behavior.
The present study describes, for the first time, an alteration of A 2A adenosine receptor signaling specifically associated with the expression of mutant Htt. Data have been obtained in a cellular system composed of immortalized striatal cells engineered to express either wild-type or mutant Htt. Using this system previously, it was found that Htt protects cells from the action of death triggers via inhibition of the caspases cascade (3). On the contrary, expression of an expanded CAG variant of Htt in the same cells led to loss of this protective effect, activation of caspases and apoptosis (3) .
In the present study we show that both parental striatal cells and the Htt- Our results also highlight profound changes of adenylyl cyclase response selectively in mutant Htt cells. Despite no changes of basal adenylyl cyclase activity, response to forskolin was significantly increased in these cells and, more remarkably, an even higher amplification of A 2A receptor-mediated cAMP formation was observed. Quite surprisingly, direct stimulation of Gprotein α-subunit with GTPγS did not result in higher adenylyl cyclase stimulation in mutant Htt cells, which suggests that this subunit is not apparently affected by the mutant protein. This finding may imply a specific effect of mutant Htt on G-protein βγ-subunits, which play key roles in both cyclase activity modulation and in mediating receptor desensitization (32) . A dysfunction of G-protein βγ-subunits leading to reduced receptor desensitization may therefore contribute to the observed aberrant amplification of A 2A receptor response. From our data it is also clear that changes of A 2A receptor signaling are much more evident in cells expressing truncated mutant Htt with respect to full-length mutant Htt. This finding may have intriguing functional implications, because the N548 fragment expressed in our cells mimics one of the potential fragments suggested to be produced by proteolytic cleavage of Htt (8, 33) and which may be required for the expression of mutant Htt cytotoxicity and aggregate formation (9, 34, 35) . Recent data demonstrate that the full-length mutant protein is processed gradually over-time in vivo to generate amino terminal fragments that accumulate into the nucleus and also in axons and synaptic terminals (36) . Truncated mutant Htt has been also demonstrated to carry significantly higher toxicity with respect to the full-length protein (9) . On this basis, one could speculate that N548mu cells may reflect a more advanced stage of the disease, where the aberrant behavior of the A 2A receptor is maximally expressed.
In our previous study (3) wild-type Htt was protecting cells from death stimuli and mutant Htt was producing cell toxicity (possibly indicating a loss of Htt function by the expanded CAG). It is interesting that, in the present report, A 2A receptor signaling was not modified by wild-type Htt but was selectively altered in mutant Htt cells. We conclude that, besides loss of the normal protective function of Htt (3), the CAG expansion in the mutant protein causes a toxic "gain-offunction" activity at the level of the A 2A receptor signal transduction mechanism, which may result in selective impairment of striatal function, possibly at very initial stages of the disease.
Our data vary with respect to a recent study in which dopamine signaling has been evaluated in R6/2 transgenic mice (31) . At a presymptomatic stage of the pathology, which precedes the emergence of histopathological and behavioral changes, response of striatal adenylyl cyclase to either the D 1 receptor agonist SKF81297 or forskolin was greatly attenuated with respect to control mice. We speculate that such differences (aberrant adenylyl cyclase stimulation in our study vs. reduced cyclase responsivity in R6/2 transgenic mice) may represent changes of striatal signaling at different stages of the pathology, and/or differences in the coupling between different receptors (D 1 or A 2A ) and adenylyl cyclase, or may depend on the fact that D1 and A 2A receptors are expressed by different sets of neurons in the basal ganglia (11) .
A possible role of this receptor in the etiopathology of HD is also consistent with literature suggesting that the A 2A receptor may contribute to cell death in ischemia-associated neurodegeneration and that A 2A receptor antagonists may indeed prove useful in preventing such damage (27, 37, 38) . In this respect, our demonstration that selective A 2A receptor antagonists retain their ability to fully block NECA-stimulated adenylyl cyclase may disclose new avenues in the pharmacological manipulation of Huntington's disease. 4 . Stimulation of cyclic AMP levels by NECA (0.1 nM-10 µM) in ST14A (•), in FL wt ( in N548 wt () (A) (EC 50 = 270 ± 10; 253 ± 11; 236 ± 13 nM, respectively), and in ST14A(•), in FL mu (), in N548 mu () (B) (EC 50 = 270 ± 10; 198 ± 15*; 93 ± 9** nM, respectively; * P<0.05; **P<0.01 vs. control). Experiments were performed as described in Materials and Methods. Curves represent the mean of four independent experiments performed in triplicate. Bars represent the mean SE.
